Results
Mankind Pharma Q2 Net Profit Rises 27% YoY
Board approved Q2 FY27 standalone net profit of ₹581.95 Cr, up 27% YoY, with revenue at ₹3,145.22 Cr.
Approved amalgamation of two wholly-owned subsidiaries, Prolijune Lifesciences and Pavi Buildwell,
